Iron metabolism is disturbed and anti-copper treatment improves but does not normalize iron metabolism in Wilson's disease

被引:17
作者
Gromadzka, Grazyna [1 ]
Wierzbicka, Diana [2 ]
Litwin, Tomasz [2 ]
Przybylkowski, Adam [3 ]
机构
[1] Cardinal Stefan Wyszynski Univ Warsaw, Fac Med, Coll Med, Woycickiego Str 1-3, PL-01938 Warsaw, Poland
[2] Inst Psychiat & Neurol, Dept Neurol 2, Sobieskiego Str 9, PL-02957 Warsaw, Poland
[3] Med Univ Warsaw, Dept Gastroenterol & Internal Med, Banacha Str 1a, PL-02097 Warsaw, Poland
关键词
Iron; Copper; Wilson disease;
D O I
10.1007/s10534-021-00289-x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Wilson's disease (WD) is a rare hereditary disorder of copper metabolism. Some data suggest that iron metabolism is disturbed in WD and this may affect the course of the disease. The current study aimed to determine whether anti-copper treatment could affect iron metabolism in WD. One hundred thirty-eight WD patients and 102 controls were examined. Serum ceruloplasmin and copper were measured by colorimetric enzyme assay or atomic adsorption spectroscopy, respectively. Routine and non-routine parameters of iron metabolism were measured by standard laboratory methods or enzyme immunoassay, respectively. WD patients, both newly diagnosed and treated, had less serum copper and ceruloplasmin than controls (90.0, 63.0, 22.0 mg/dL, respectively, p < 0.001); in the treated patients blood copper and ceruloplasmin were lower than in untreated patients (p < 0.001). Untreated patients (n = 39) had a higher median blood iron (126.0 vs 103.5 ug/dL, p < 0.05), ferritin (158.9 vs 47.5 ng/mL, p < 0.001), hepcidin (32, 6 vs 12.1 ng/mL, p < 0.001) and sTfR (0.8 vs. 0.7 ug/mL, p < 0.001) and lower blood transferrin (2.4 vs. 2.7 g/L, p < 0.001), TIBC (303.0 vs 338.0 ug/dL, p < 0.001), hemoglobin (13.1 vs 13.9 g/dL, p < 0.01) and RBC (4.3 vs. 4.6, p < 0.002) than controls. Treated patients (n = 99) had a significantly lower median iron (88.0 vs. 126.0 ug/dL, p < 0.001), ferritin (77.0 vs. 158.9 ng/mL, p < 0.005) and hepcidin (16.7 vs. 32.6 ng/mL, p < 001) and higher transferrin (2.8 vs. 2.4 g/L, p < 0.005), TIBC (336.0 vs 303.0 ug/dL, p < 0.001), RBC (4.8 vs. 4.3 M/L, p < 0.001) and hemoglobin (14.4 vs. 13.1 g/dL, p < 0.001) than untreated; the median iron (p < 0.005) was lower, and ferritin (p < 0.005), RBC (p < 0.005) and hepcidin (p < 0.002) were higher in them than in the control group. Changes in copper metabolism are accompanied by changes in iron metabolism in WD. Anti-copper treatment improves but does not normalize iron metabolism.
引用
收藏
页码:407 / 414
页数:8
相关论文
共 27 条
[1]   Lactoferrin: a review [J].
Adlerova, L. ;
Bartoskova, A. ;
Faldyna, M. .
VETERINARNI MEDICINA, 2008, 53 (09) :457-468
[2]   Wilson's disease [J].
Ala, Aftab ;
Walker, Ann P. ;
Ashkan, Keyoumars ;
Dooley, James S. ;
Schilsky, Michael L. .
LANCET, 2007, 369 (9559) :397-408
[3]   The physiology of lactoferrin [J].
Brock, JH .
BIOCHEMISTRY AND CELL BIOLOGY, 2002, 80 (01) :1-6
[4]   Hepatic Iron Deposition in Patients With Liver Disease: Preliminary Experience With Breath-Hold Multiecho T2*-Weighted Sequence [J].
Chandarana, Hersh ;
Lim, Ruth P. ;
Jensen, Jens H. ;
Hajdu, Cristina H. ;
Losada, Mariela ;
Babb, James S. ;
Huffman, Steve ;
Taouli, Bachir .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2009, 193 (05) :1261-1267
[5]   Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI - histopathological study [J].
Dusek, P. ;
Bahn, E. ;
Litwin, T. ;
Jablonka-Salach, K. ;
Luciuk, A. ;
Huelnhagenk, T. ;
Madai, V. I. ;
Dieringer, M. A. ;
Bulska, E. ;
Knauth, M. ;
Niendorf, T. ;
Sobesky, J. ;
Paul, F. ;
Schneider, S. A. ;
Czlonkowska, A. ;
Brueck, W. ;
Wegner, C. ;
Wuerfel, J. .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2017, 43 (06) :514-532
[6]   Diagnosis and phenotypic classification of Wilson disease [J].
Ferenci, P ;
Caca, K ;
Loudianos, G ;
Mieli-Vergani, G ;
Tanner, S ;
Sternlieb, I ;
Schilsky, M ;
Cox, D ;
Berr, F .
LIVER INTERNATIONAL, 2003, 23 (03) :139-142
[7]   Frameshift and nonsense mutations in the gene for ATPase7B are associated with severe impairment of copper metabolism and with an early clinical manifestation of Wilson's disease [J].
Gromadzka, G ;
Schmidt, HHJ ;
Genschel, J ;
Bochow, B ;
Rodo, M ;
Tarnacka, B ;
Litwin, T ;
Chabik, G ;
Czlonkowska, A .
CLINICAL GENETICS, 2005, 68 (06) :524-532
[8]   Difference in iron metabolism may partly explain sex-related variability in the manifestation of Wilson's disease [J].
Gromadzka, Grazyna ;
Wierzbicka, Diana ;
Litwin, Tomasz ;
Przybylkowski, Adam .
JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2020, 62
[9]   Gene variants encoding proteins involved in antioxidant defense system and the clinical expression of Wilson disease [J].
Gromadzka, Grazyna ;
Kruszynska, Monika ;
Wierzbicka, Diana ;
Litwin, Tomasz ;
Dziezyc, Karolina ;
Wierzchowska-Ciok, Agata ;
Chabik, Grzegorz ;
Czlonkowska, Anna .
LIVER INTERNATIONAL, 2015, 35 (01) :215-222
[10]   Genetic variability in the methylenetetrahydrofolate reductase gene (MTHFR) affects clinical expression of Wilson's disease [J].
Gromadzka, Grazyna ;
Rudnicka, Magdalena ;
Chabik, Grzegorz ;
Przybylkowski, Adam ;
Czlonkowska, Anna .
JOURNAL OF HEPATOLOGY, 2011, 55 (04) :913-919